← Compound index
COMPOUND RECORD / CHLODANTANE

ChlodantaneХлодантан

N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.

PerformanceStress
Source linked

What the studies found

Experiment described in a patent · 2019

Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures

Study of multiple preparations

Cold-exposure motor coordination
24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) sp=0.04 versus cold control
Sydnocarb comparator
6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiorityp=0.04

The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.

Study notes · methods, sources and limitations

Participants or model Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Design Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Important limitations

  • Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure. The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product. The groups were small, and the source gives conflicting comparison-group sizes.
  • These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.

RU2704126C2; filed 28 November 2016 · Patent report

Original source or citation ↗

Study results and tables ↗

Animal research · 2006

Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane

Study of multiple preparations

The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.

Study notes · methods, sources and limitations

Participants or model Experimental animal tissue-distribution study; human participants not reported.

Important limitations

  • The accessible material is an introduction, conclusions and bibliography transcribed by a third party, not the complete dissertation. Concentration-time tables, half-lives and tissue-specific exposure estimates were not recovered. Occupational-use statements in the introduction concern actoprotectors collectively and do not document a Chlodantane-treated human cohort.

Candidate of Medical Sciences dissertation. Volgograd, 2006; 124 pages according to catalogue metadata · Dissertation abstract; third-party transcription

Original source or citation ↗

Study results and tables ↗

Animal research · 2023

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

Study of multiple preparations

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Study notes · methods, sources and limitations

Participants or model Mouse pharmacology experiments

Important limitations

  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety. An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose. The Russian and English versions are one publication, not independent replication.

Pharmaceutical Chemistry Journal. 57(4):523–534 · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Chlodantane

Names in this research collection

ADK-910 · Chlondatane · Chlodantan

Identity / background source ↗

Research background

N-(adamantan-2-yl)-4-chlorobenzamide, an experimental benzamide from the Russian adamantane program. Its amide linkage distinguishes it from Bromantane’s arylamine.

Archival sources and remaining questions ↗

CLINICAL DEVELOPMENT / SOURCE CHECKED 1 NOVEMBER 2026

Clinical testing reported by Sirius University

Sirius University’s announcement of 21 February 2023 states that Chlodantane completed the necessary stages of clinical studies. This is a newly highlighted historical source, rather than an announcement of a new 2026 trial.

The announcement supplies no trial identifier, phase, participant count or clinical results. Its statement does not independently establish marketing authorization, human efficacy or safety.

Read the announcement translation and clinical-development history ↗

Compound class
Experimental adamantane / analogue
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Institutional statements describe clinical testing; no primary human-trial report verified

Study methods

Animal pharmacology, tissue-distribution research, chemical-method papers and historical documents

Independent replication

Independent replication not established; translations are not separate experiments

Source access

Access and review depth appear with each linked record

Safety evidence

Human safety and interactions not established; animal activity is not a safe-use recommendation

Open a topic for the evidence assessment.

More findings, background and history

Chlodantane, Cyclontane and the ADK research program ↗

What remains unclear

Sirius University described clinical testing in 2023. The original trial records would identify investigators, study sites, enrollment, dates and outcomes. Complete 1995 and 2006 pharmacokinetic tables and the relationship between ADK-919 and ADK-910 remain open questions.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 3 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2019 · RU2704126C2 · Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperaturesUse · 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls

Reported findings

The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.

Cold-exposure motor coordination
24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) s
Sydnocarb comparator
6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiority
All reported results, comparisons and limitations →

Use. Later Chlodantane use claims; Bromantane served as a comparator.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2704126C2 ↗ · 2019-10-24
Earliest priority / filing
2016-11-28 / 2016-11-28
Original applicant / assignee
Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62557483 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition based on chlorobenzoylaminoadamantane, which increases physical performance in high and low temperatures

Inventors: Сергей Борисович Середенин; Григорий Георгиевич Незнамов; Валерий Гаврилович Барчуков; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Сергей Александрович Крыжановский; Иосиф Борисович Цорин; Валерий Николаевич Столярук; Марина Борисовна Вититнова.

RU2704126C2

Original patent PDF ↗

Read source review →

2018 · RU2660654C1 · Phenoxyacetamide structural analogues of Chlodantane and ADK-918Platform context · 15.1 g, 85% yield

Reported findings

The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.

Analogue 1 recovery
15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Analogue 2 recovery
80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization
All reported results, comparisons and limitations →

Platform context. The claimed phenoxyacetamides are described as structural analogues of ADK-910 and ADK-918, rather than claims to those reference compounds themselves.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2660654C1 ↗ · 2018-07-09
Earliest priority / filing
2017-06-09 / 2017-06-09
Original applicant / assignee
Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ)
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62815866 · family publications are related filings, not independent studies.
Original title, inventors and related publications

N-(adamantan-2-yl)- and n-[(adamantan-1-yl)methyl]- derivatives of 2-(4-allyl-2-methoxyphenoxy)acetic acid amide, which are potential synthetic adaptogens of emergency action

Inventors: Иван Александрович Новаков; Лейла Липпаритовна Брунилина; Андрей Александрович Вернигора; Максим Борисович Навроцкий; Борис Семёнович Орлинсон; Александр Сергеевич Яблоков.

RU2660654C1

Original patent PDF ↗

Read source review →

1996 · SU1646256A1 · Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulationMolecule · Not available in the accessed bibliographic entry

Experimental results unavailable in the source

Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.

Original experimental outcomes
Not available in the accessed bibliographic entryNo animal survival percentage or human performance effect is invented
All reported results, comparisons and limitations →

Molecule. Historical chloro- and bromo-benzoylaminoadamantane disclosure in the Chlodantane development trail. It must not be conflated with Bromantane solely because bromine is mentioned.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
SU1646256A1 ↗ · 1996-06-10
Earliest priority / filing
1989-07-13 / 1989-07-13
Original applicant / assignee
Научно-исследовательский институт фармакологии АМН СССР
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
60531599 · family publications are related filings, not independent studies.
Original title, inventors and related publications

2-(para-bromobenzoyl) or 2-(para-chlorobenzoyl)-aminoadamantanes increasing organism resistance to environment inhabitation extremal factor effect and showing immunostimulating activity

Inventors: И.С. Морозов; Н.Г. Арцимович; Н.В. Климова; Т.А. Фадеева; Н.М. Зайцева; Т.С. Галушина; Н.П. Быков; Б.М. Пятин; Н.И. Авдюнина; О.В. Щербакова; Г.В. Пушкарь; В.В. Каштанова; Т.Г. Хлопушина; Г.А. Кузнецова; И.А. Иванова; А.С. Лосев; Л.П. Ефимова; В.Г. Барчуков; С.А. Сергеева; Т.Д. Карпова; О.В. Агафонова; О.М. Краснова; С.Б. Середенин; Б.А. Бадыштов.

SU1646256A1

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2006

Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane

The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.

Study notes and original source
2006Animal / experimentalFull text available

Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane

Experimental Chlodantane; source-specific preparation · Dissertation abstract; third-party transcription

Format: Dissertation abstract transcription · Reviewed: Author-abstract transcription: introduction, conclusions and bibliography checked; full dissertation not recovered

A. V. Safronenko · Candidate of Medical Sciences dissertation. Volgograd, 2006; 124 pages according to catalogue metadata

The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.

Population / setting
Experimental animal tissue-distribution study; human participants not reported.
Source reviewed
Author-abstract transcription: introduction, conclusions and bibliography checked; full dissertation not recovered
Study limitations
  • The accessible material is an introduction, conclusions and bibliography transcribed by a third party, not the complete dissertation. Concentration-time tables, half-lives and tissue-specific exposure estimates were not recovered. Occupational-use statements in the introduction concern actoprotectors collectively and do not document a Chlodantane-treated human cohort.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2001

Toxicological characterization of new psychotropic drugs of the actoprotector and nootropic classes

The author reports that preclinical dossiers including Chlodantane, Bromantane and Bromitil were submitted to the Pharmacological Committee and supported recommendation for clinical investigation. The same work describes dose-dependent reproductive and blood-cell effects in animals.

Study notes and original source
2001Animal / experimentalFull text available

Toxicological characterization of new psychotropic drugs of the actoprotector and nootropic classes

Experimental Chlodantane; source-specific preparation · Dissertation abstract; third-party transcription

Format: Dissertation abstract transcription · Reviewed: Third-party transcription of author-abstract sections and conclusions checked; full dissertation and committee dossier not recovered

L. I. Bugaeva · Doctor of Biological Sciences dissertation. Volgograd, 2001

The author reports that preclinical dossiers including Chlodantane, Bromantane and Bromitil were submitted to the Pharmacological Committee and supported recommendation for clinical investigation. The same work describes dose-dependent reproductive and blood-cell effects in animals.

Population / setting
Preclinical animal toxicology program; no human trial cohort documented in the accessible text.
Source reviewed
Third-party transcription of author-abstract sections and conclusions checked; full dissertation and committee dossier not recovered
Study limitations
  • A statement about submission or recommendation is not the committee decision itself, a trial authorization number, evidence of administration to volunteers, or proof of completed clinical trials. Animal toxicology rankings do not establish human safety. Related reproductive publications may overlap this program.

Reviewed 2026-11-01.

Read the source ↗

Lab research · 2023

Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors

The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.

Study notes and original source
2023In vitroFull text available

Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors

Cage-amide family; lead 18a distinct from Chlodantane; Bromantane also tested · Journal publication

E. S. Mozhaitsev, E. V. Suslov, D. A. Rastrepaeva, O. I. Yarovaya, S. S. Borisevich, E. M. Khamitov, D. S. Kolybalov, S. G. Arkhipov, N. I. Bormotov, L. N. Shishkina, O. A. Serova, R. V. Brunilin, A. A. Vernigora, M. B. Nawrozkij, A. P. Agafonov, R. A. Maksyutov, K. P. Volcho, N. F. Salakhutdinov · Viruses. 2023;15(1):29. PMID 36680072; PMCID PMC9865139

The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.

Population / setting
Cultured-cell antiviral and cytotoxicity comparisons of cage-amide compounds, with computational target modelling; no human participants.
Source reviewed
Original full-text XML reviewed via Europe PMC, including findings, tables and interpretation; procedural chemistry and virology are not reproduced here
Study limitations
  • Cell-culture activity does not establish treatment benefit in people. Selectivity index compares cytotoxicity and antiviral concentrations in the assay; it is not a human therapeutic index. The strongest family result must not be transferred to Chlodantane. The paper does not substantiate the Sirius news release’s claim of historical human testing.

Reviewed 2026-11-01.

Read the source ↗

Laboratory analysis · 2025

A sustainable twist on the Ritter reaction: iron-based deep eutectic solvents as a green route to amide synthesis

The publication uses Chlodantane as a gram-scale demonstration of a reusable reaction medium for amide chemistry. It reports an 89% isolated yield for that demonstration and evaluates process sustainability. Its significance is continued chemical-method development and analytical characterization, rather than evidence of clinical effectiveness.

Study notes and original source
2025Analytical / composition studyFull text available

A sustainable twist on the Ritter reaction: iron-based deep eutectic solvents as a green route to amide synthesis

Chlodantane chemical-method demonstration; ADK code discrepancy noted · Journal publication

Luciana Cicco, Arfa Yousaf, Paola Vitale, Filippo Maria Perna, Vito Capriati · RSC Sustainability. 2025;3:4079–4086. First published 15 July 2025; CC BY 3.0

The publication uses Chlodantane as a gram-scale demonstration of a reusable reaction medium for amide chemistry. It reports an 89% isolated yield for that demonstration and evaluates process sustainability. Its significance is continued chemical-method development and analytical characterization, rather than evidence of clinical effectiveness.

Population / setting
Chemical synthesis and analytical characterization; no animal or human pharmacology experiment.
Source reviewed
Review based on the publisher abstract, citation and selected article passages. The full PDF was unavailable.
Study limitations
  • The article labels the example ADK-919, whereas the historical Chlodantane records use ADK-910. That discrepancy is retained and ADK-919 is not adopted as a confirmed synonym. Chemical yield, purity and process reuse are not pharmacological efficacy or human safety outcomes.

Reviewed 2026-11-01.

Read the source ↗

Experiment described in a patent · 2019

Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures

The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.

Study notes and original source
2019Patent / reported experimentsFull text available

Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures

Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

· RU2704126C2; filed 28 November 2016

The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.

Results and tables

Reported patent results

Reported findings

The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.

Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Population or model Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Results · Description: final hypothermia/Rotarod experiment and narrative accompanying Table 5.
MeasureResultComparison, timing and statistics
Cold-exposure motor coordination24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control
Sydnocarb comparator6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiority · p=0.04

These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
  • The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
  • The groups were small, and the source gives conflicting comparison-group sizes.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2023

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Study notes and original source
2023Animal / experimentalFull text available

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Population / setting
Mouse pharmacology experiments
Source reviewed
Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
  • An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
  • The Russian and English versions are one publication, not independent replication.

Reviewed 2026-10-03.

Read the source ↗

Laboratory analysis · 2019

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Study notes and original source
2019Analytical / composition studyFull text available

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Population / setting
Chemical synthesis and characterization; background pharmacology citations
Source reviewed
Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Study limitations
  • Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
  • ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.

Reviewed 2026-10-03.

Read the source ↗

Animal research · Year unconfirmed

Role of neurotropic adamantane-containing compounds in the regulation of immunity

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Study notes and original source
Year unconfirmedAnimal / experimentalRussian-language source

Role of neurotropic adamantane-containing compounds in the regulation of immunity

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

· Dissertation author’s abstract; third-party Russian transcription

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Population / setting
Multiple mouse strains and laboratory immune assays
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
  • Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.

Reviewed 2026-10-03.

Read the source ↗

Animal research · 1996

Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects

ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.

Study notes and original source
1996Animal / experimentalRussian-language source

Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996

ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.

Population / setting
Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Original structures and tables require checking against the scan; transcription errors are possible.
  • Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
  • Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.

Reviewed 2026-10-03.

Read the source ↗

Experiment described in a patent · 1996

Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation

The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.

Study notes and original source
1996Patent / reported experimentsBibliographic record

Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation

· SU1646256A1

The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.

Results and tables

Reported patent results

Experimental results unavailable in the source

Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.

The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.

Population or model The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.

Results · Accessed original-publication index entry; description and result tables unavailable.
MeasureResultComparison, timing and statistics
Original experimental outcomesNot available in the accessed bibliographic entryNo animal survival percentage or human performance effect is invented

The original certificate is unavailable. Whether it contains experimental results remains unknown.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
Source reviewed
Bibliographic index entry accessed. No readable original experimental description or results tables were available; quantitative extraction requires the original publication.
Study limitations
  • Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
  • Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2018

Phenoxyacetamide structural analogues of Chlodantane and ADK-918

The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.

Study notes and original source
2018Patent / reported experimentsFull text available

Phenoxyacetamide structural analogues of Chlodantane and ADK-918

· RU2660654C1; Volgograd State Technical University

The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.

Results and tables

Reported patent results

Reported findings

The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.

Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Population or model Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Results · Final two chemical examples and characterization results.
MeasureResultComparison, timing and statistics
Analogue 1 recovery15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Analogue 2 recovery80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization

Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-11-06.

Read the source ↗

Laboratory analysis · 2019

Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction

Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.

Study notes and original source
2019Analytical / composition studyRussian-language source

Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction

· Zhurnal Organicheskoi Khimii. 55(11):1781–1788

Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗

Review of earlier studies · 1999

Adamantane derivatives enhancing body's resistance to emergencies

Summarizes screening of adamantane derivatives and distinguishes Bromantane from the chemically different Chlodantane.

Study notes and original source
1999ReviewEnglish abstract

Adamantane derivatives enhancing body's resistance to emergencies

Morozov IS, Klimova NV, Sergeeva SA, Ivanova IA, Barchukov VG, Kovalev GI, Piatin BM, Avdiunina NI · Vestnik Rossiiskoi akademii meditsinskikh nauk (3):28-32. PMID 10222828

Summarizes screening of adamantane derivatives and distinguishes Bromantane from the chemically different Chlodantane.

Population / setting
Experimental adamantane-development program and animal stress models
Source reviewed
Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
  • A development-program summary is not an independent human trial.
  • Historical claims about specific military deployments need their own contemporary documentation.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗